<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452359</url>
  </required_header>
  <id_info>
    <org_study_id>CS0315</org_study_id>
    <nct_id>NCT02452359</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Using Intense Pulsed Light for Improving the Appearance of Striae Distensae</brief_title>
  <official_title>Clinical Evaluation of Venus Versa SR Applicator Using Intense Pulsed Light on Skin Texture for Improving the Appearance of Striae Distensae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Venus Concept</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Venus Concept</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is intended to evaluate the effect of IPL treatment on the Striae Distensae. The&#xD;
      study hypothesis is that the SR580 applicator will improve the appearance of Striae Distensae&#xD;
      by at least 1 point on the Global Aesthetic Improvement ScaleI (GAIS) at 3 months follow-up&#xD;
      compared to baseline in at least 50% of the study population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design This is a multi-site, prospective, open labeled clinical trial with before-after&#xD;
      study design. This study will include up to 8 visits at the clinic: initial&#xD;
      screening/consultation, 5 treatments, visits in 2 week intervals, and 2 follow-up visits at 1&#xD;
      and 3 months after the last treatment visit.&#xD;
&#xD;
      Up to 60 healthy subjects age 24-65 with Striae Distensae will be enrolled.&#xD;
&#xD;
      Study duration:&#xD;
&#xD;
      Duration of subject's participation: Up to 5.5 months from enrollment to termination&#xD;
&#xD;
      Blinding Objective assessment of clinical improvement by global assessment scale will be&#xD;
      achieved by sending before/after pictures (baseline/3months after last treatment) to 3&#xD;
      blinded reviewers at the end of the study.&#xD;
&#xD;
      Study Procedures Test Spots Up to 3 test spots will be performed in the selected treatment&#xD;
      area to determine the optimal parameters / settings&#xD;
&#xD;
      Treatment visits Each subject will be enrolled and scheduled for 5 treatments at 2 week&#xD;
      intervals and return for follow-up visits at one month and 3 months after the last treatment&#xD;
      for evaluation of the treated areas. The duration of the entire treatment visit is&#xD;
      approximately 60 minutes.&#xD;
&#xD;
      Treatment The treatment areas are divided into 2 treatment areas: abdomen or thighs. Apply a&#xD;
      thin layer of IPL gel. Place the applicator in close contact, perpendicular to the skin with&#xD;
      no pressure applied. Pressing the applicator will fire the IPL pulse.&#xD;
&#xD;
      Administer pulses throughout the treated area to ensure full coverage of the treated area&#xD;
      with applicator overlap approximately 1/3 of the previously treated skin.&#xD;
&#xD;
      A single pass over the area is completed Remove the remnants of the IPL gel and dry&#xD;
      thoroughly. Cold air or cold, wet but not frozen gauze pads may be placed on the treated area&#xD;
      for post treatment cooling.&#xD;
&#xD;
      Typical responses to the treatment are mild erythema and edema.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Continuing the trial was considered to be superfluous.&#xD;
  </why_stopped>
  <start_date type="Actual">March 13, 2015</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">February 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label study where all subjects assigned to receive 5 treatments every 2 weeks. Subjects acted as their own control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Striae Distensae Appearance</measure>
    <time_frame>90 days following last IPL treatment</time_frame>
    <description>Striae distensae appearance improvement by at least 1 point on the Global Aesthetic Improvement scale (GAIS) from photographs 3 months following the last treatment as determined by 3 blinded reviewers where 3 = Very Much Improved, 2 = Much Improved, 1 = Improved, 0 = No Change, -1 = Worse, -2 = Much Worse and -3 = Very Much Worse.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Striae Distensae</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group receiving treatment with Venus Versa IPL energy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Venus Versa</intervention_name>
    <description>The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide written Informed Consent;&#xD;
&#xD;
          2. Healthy male or female, 24-65 years Fitzpatrick-Goldman skin type I-V;&#xD;
&#xD;
          3. Having visible Striae Distensae to be treated (abdomen/thighs);&#xD;
&#xD;
          4. Comply with the treatment/follow-up schedule and requirements;&#xD;
&#xD;
          5. Women of child-bearing age are required to be using a reliable method of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Fitzpatrick-Goldman skin type VI;&#xD;
&#xD;
          2. Pregnant, intending to become pregnant during the course of study, less than 3 months&#xD;
             postpartum or less than 6 weeks after breastfeeding;&#xD;
&#xD;
          3. Heavy smoker&#xD;
&#xD;
          4. Unable or unlikely to refrain from tanning&#xD;
&#xD;
          5. Use of photosensitive medication&#xD;
&#xD;
          6. Use of oral isotretinoin within 3 months&#xD;
&#xD;
          7. Any dermal/epidermal damage or disorder in treated area&#xD;
&#xD;
          8. Prior treatment in treated area within 3 months&#xD;
&#xD;
          9. Prior skin laser/light or another device treatment in treated area within 6 months&#xD;
&#xD;
         10. Prior use of collagen, fat injections or other methods of skin augmentation in treated&#xD;
             area within 12 months&#xD;
&#xD;
         11. Prior use of Botox in treatment area within 6 months&#xD;
&#xD;
         12. Prior ablative resurfacing procedure with laser in treatment area within 12 months&#xD;
&#xD;
         13. Any other surgery in treated area within 9 months&#xD;
&#xD;
         14. Participation in a study of another investigational device or drug as per the&#xD;
             Investigator's discretion&#xD;
&#xD;
         15. History of keloid or any other type of hypertrophic scar formation or poor wound&#xD;
             healing in a previously injured skin area&#xD;
&#xD;
         16. Showing symptoms of hormonal disorders (such as Melasma, Chloasma);&#xD;
&#xD;
         17. Concurrent inflammatory skin conditions, open laceration or abrasion of any sort on&#xD;
             area to be treated during the course of treatment&#xD;
&#xD;
         18. Active Herpes Simplex at the time of treatment or having experienced more than three&#xD;
             episodes of Herpes Simplex eruption within a year of study&#xD;
&#xD;
         19. Multiple dysplastic nevi in area to be treated&#xD;
&#xD;
         20. Having a bleeding disorder or taking anticoagulation medications&#xD;
&#xD;
         21. History of immunosuppression/immune deficiency disorders&#xD;
&#xD;
         22. Having any form of active cancer at the time of enrollment and during the course of&#xD;
             the study or history of skin cancer&#xD;
&#xD;
         23. Pigmented lesion in the treated area that appears cancerous&#xD;
&#xD;
         24. Significant concurrent illness, such as uncontrolled diabetes&#xD;
&#xD;
         25. Active infections in the treated area&#xD;
&#xD;
        28.Tattoo or permanent makeup at the treatment area. 29.Mentally incompetent, prisoner or&#xD;
        evidence of active substance or alcohol abuse 30.Any condition which, in the Investigator's&#xD;
        opinion, would make it unsafe (for the subject or for the study personnel) to treat the&#xD;
        subject as part of this research study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracey L Mancuso</last_name>
    <role>Study Director</role>
    <affiliation>Venus Concept</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rosenberg Plastic Surgery</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <results_first_submitted>March 9, 2018</results_first_submitted>
  <results_first_submitted_qc>October 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 3, 2020</results_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stretch marks</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Striae Distensae</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 11, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02452359/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Each subject to receive IPL 580 nm treatment to striae distensae on either abdomen or thighs. Baseline photos taken of untreated treatment area.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IPL 580 nm Treatment</title>
          <description>Each subject to receive IPL applicator SR580 treatment of Striae Distensae either on the abdomen or thighs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Group receiving treatment with Venus Versa IPL energy&#xD;
Venus Versa: The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.&#xD;
IPL gel: water based gel used to protect the skin during light based treatments. Is also commonly used during ultrasound treatments.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline photograph of treatment area</title>
          <description>Body area with visible Striae Distensae, either abdomen or thighs.</description>
          <population>The baseline photographs were not evaluated.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Striae Distensae Appearance</title>
        <description>Striae distensae appearance improvement by at least 1 point on the Global Aesthetic Improvement scale (GAIS) from photographs 3 months following the last treatment as determined by 3 blinded reviewers where 3 = Very Much Improved, 2 = Much Improved, 1 = Improved, 0 = No Change, -1 = Worse, -2 = Much Worse and -3 = Very Much Worse.</description>
        <time_frame>90 days following last IPL treatment</time_frame>
        <population>The primary outcome measure is not reported as data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Group receiving treatment with Venus Versa IPL energy&#xD;
Venus Versa: The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.&#xD;
IPL gel: water based gel used to protect the skin during light based treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Striae Distensae Appearance</title>
          <description>Striae distensae appearance improvement by at least 1 point on the Global Aesthetic Improvement scale (GAIS) from photographs 3 months following the last treatment as determined by 3 blinded reviewers where 3 = Very Much Improved, 2 = Much Improved, 1 = Improved, 0 = No Change, -1 = Worse, -2 = Much Worse and -3 = Very Much Worse.</description>
          <population>The primary outcome measure is not reported as data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year 11 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IPL 580 nm Treatment</title>
          <description>All subjects who received at least one IPL treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yoni Iger</name_or_title>
      <organization>Venus Concept Ltd</organization>
      <phone>888-907-0115</phone>
      <email>yoni@venusconcept.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

